LIBERVANT FDA Decision: Eton Pharmaceuticals, Inc. (ETON)

The PDUFA date for LIBERVANT by Eton Pharmaceuticals, Inc. (ETON) is scheduled for March 29, 2027. This is the target date for the FDA to make a decision on this application.

LIBERVANT is being developed by Eton Pharmaceuticals, Inc. for the treatment of acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 to 5 years of age and 12 years of age and above. It is under FDA review.

If LIBERVANT receives FDA approval, Eton Pharmaceuticals, Inc. (ETON) would be able to market the drug in the United States for acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 to 5 years of age and 12 years of age and above. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for ETON on DilutionWatch at dilutionwatch.com/stock/ETON.html.

You can view the full BiotechSign company profile for Eton Pharmaceuticals, Inc. (ETON) at biotechsign.com/company/ETON, which includes the BiotechSign Score, signal history, clinical trial data, and insider trading activity.